Search
  • Site Search
  • News
  • Product
  • Zhejiang Medical Technology Development Co., Ltd.

    2020 year
    11
    14 day
    Establishment of Bo’ao Winhealth Rare Disease Medical Center in Hainan Province


    On November 14, 2020, witnessed by all its distinguished guests, the 'Bo’ao Winhealth Rare Disease Medical Center', jointly founded by Boao Lecheng International Medical Tourism Pilot Zone Administration, Winhealth Pharma Group (HK) and Bo'ao Future Hospital, was officially launched, with its first experts forum being kicked off simultaneously in Bo'ao Future Hospital of Boao Lecheng International Medical Tourism Pilot Zone Administration.


    Establishment of Bo’ao Winhealth Rare Disease Medical Center in Hainan Province

     

    Li Wenxiu, deputy director of Hainan Provincial Health Commission, Li Yunda, deputy director of Hainan Medical Products Administration, Liu Zhefeng, deputy director of Hainan Bo'ao International Medical Tourism Pilot Zone Administration, Wang Wei, founder / Chairman / CEO of Winhealth Pharma Group (HK), Zhang Xiaoqing, President of Bo'ao Future Hospital, Li Dingguo, director general of Shanghai Foundation for Rare Disease, and Wang Yiou, secretary general / founder of Beijing Illness Challenge Foundation and Francois Liot, China region general manager of Ethypharm Pharmaceutical Co. Ltd. , attended the meeting and delivered their speeches.

    Other participants included Hu Shanshan, deputy director of the Medical Administration Bureau of Hainan Provincial Health Commission; Wang Gang, director of Drug Registration and Production Department of Hainan Medical Products Administration; Han Hui, director of Hainan Bo'ao Medical Products Administration; Shi Yingming, chairman of Bo'ao Future Hospital; Zhang Xiaoqing, president of Bo'ao Future Hospital; Hao Jinghui, co-CEO of Winhealth Pharma Group (HK), and Xiao Li, vice president/director of Bo’ao Winhealth Rare Disease Medical Center, and representatives from Chinese Organization for Rare Disorders, Chengdu Echo Rare Disease & Children Caring Center, Kyowa Kirin, Ethypharm Pharmaceutical Co. Ltd., Daiichi Sankyo, Ernst & Young (Shanghai) Tax Accounting Services, Ernst & Young (Shanghai) Tax Agent, Ernst & Young Huaming Accounting Firm, UCB Pharma, Guangzhou Baiji Xinte Pharmaceutical, Citrine Medicine Limited and other enterprises. More than 30 media were invited to the conference.

    The communique of the Fifth Plenum of the 19th CPC National Congress proposed to comprehensively promote the construction of a healthy China and implement the national strategy of actively coping with the aging population. It is of great significance to ensure and improve people's livelihood, enhance people's health level, and constantly meet people's growing needs for a better life. Rare diseases feature very low incidence and prevalence rate. However, due to a large population base, China has big number of patients with rare diseases, estimated over 20 million. Rare diseases are not only a medical problem, but also a social problem.

     

    Zhang Xiaoqing, president of Bo'ao Future Hospital, pointed out that the hospital will try to attract more well-known domestic or foreign medical institutions, establish specialized diagnosis and treatment departments, and provide high-level, high-quality medical services for patients. In the future, Bo'ao Future Hospital will join hands with Bo’ao Winhealth Rare Disease Medical Center, giving full play to their respective advantages, making good, smart use of the 'early and pilot implementation' policy that the nation gave to Lecheng Pilot Zone, serve the rare disease patients in Hainan, China and other surrounding areas, and make an important contribution for the development of Lecheng.

     

    Wang Wei, chairman of Winhealth Pharma Group (HK), said that Winhealth Pharma Group (HK) has always dedicated to addressing more unmet medical needs. Rare diseases involve multiple fields and generate huge unmet medical demands. To focus on rare diseases is one of the important strategic layouts of Winhealth Pharma Group (HK) in China and in Southeast Asia. At present, the accessibility of rare disease products in the Chinese market is still far lower than that in the developed countries in Europe, the United States and Japan. On the one hand, the NMPA is speeding up approval for marketing of rare disease products; on the other hand, the Rare Disease Medical Center constantly introduces and innovate rare disease products to help improve accessibility to benefit the vast Chinese patients with rare diseases, and further reduces the gap between rare disease products from China and its surrounding areas and those pfrom the European, American and Japanese markets. This will be of great historical significance.

     

    Liu Zhefeng, deputy director of Hainan Bo'ao International Medical Tourism Pilot Zone Administration, said that he would like to thank Winhealth Pharma Group (HK) for its support to the rare disease career in Lecheng. On June 2020, the introduction of both the innovative medicines and devices and the available new drugs for tumor and rare diseases products broke through 'double 100' in Lecheng. The establishment of the Center is highly consistent with the overall development orientation of 'six centers in three places' in the pilot zone, and is an establishment of an international medical exchange center under the background of a free trade port. We hope to take this as an opportunity to gradually transit to, and really become a rare disease medical center at national level, and finally take a lead worldwide in drug marketing.

     

    Li Yunda, deputy director of Hainan Medical Products Administration, pointed out that the establishment of Bo’ao Winhealth Rare Disease Medical Center will attract more internationally well-known pharmaceutical enterprises to actively introduce innovative medicines and devices to Lecheng, so that more patients with rare diseases can receive the world’s most advanced treatment and services in Lecheng. Meanwhile, the real-world data research in the rare disease field will be conducted to promoting the development of clinical researches of drugs, and medicines and devices for rare diseases, further accelerating their approval and marketing, and finally benefiting more patients in China.

     

    Li Wenxiu, deputy director of Hainan Health Commission, said that the Commission attached great importance to the national medical environment safety and people's health conditions, and would give full support to the work of the Center, provide all-round guidance to improve the medical treatment quality, and strengthen the review and management of expert qualifications, so as to create a comprehensive, multi-department and high-quality environment of diagnosis and treatment of the vast patients with rare diseases in China, and escort for the development of the career fighting rare diseases.

     

    Li Dingguo, chairman of the Shanghai Foundation for Rare Disease, delivered a speech as an expert representative. He indicated that to promote the career of treating rare diseases requires wisdom more than knowledge, humane sentiments more than emotions, and insistence more than support because only insistence brings hope. Wang Yiou, secretary general / founder of Beijing Illness Challenge Foundation, said on behalf of the Rare Disease Patients' Organizations that patients with rare diseases still face a lot of difficulties in drug accessibility as many such drugs have not been introduced into China. As a platform for the patients and the patients' organizations, the Foundation hopes to work with the Center and other parties in the implementation of Bo'ao Policies, so that such patients can really reach and afford relevant drugs; Francois Liot, China region general manager of Ethypharm Pharmaceutical Co. Ltd., said that the establishment of Bo’ao Winhealth Rare Disease Medical Center is a good opportunity to help relevant drugs achieve early market access.

     

    Xiao Li, executive director of Bo’ao Winhealth Rare Disease Medical Center, said that the Center has established good cooperative relations with various professional associations of rare diseases, authoritative medical institutions, expert groups, rare disease patients' organizations and a number of Chinese and foreign rare disease drug producers since April 2020, when the Center got authorization from the Lecheng Medical Tourism Pilot Zone Administration. The center will live up to the mission of ' To become the most comprehensive and advanced rare disease clinical medical center with the most advanced diagnosis and treatment services in China, Southeast Asia and other surrounding areas.', forge ahead and actively explore for building a nation-level rare disease center. Director Xiao Li specifically introduced the functions of the Center, such as bringing in the most advanced medicines and devices and medical technologies for rare diseases; attracting both Chinese and foreign authoritative teams of rare disease experts to provide the most high-end diagnosis and treatment services; cooperating with domestic and foreign manufacturers, commercial insurance companies, charities and public welfare funds, etc., actively exploring innovative payment modes and carrying out patient-assisting projects to solve the medication problem of 'the last mile'; undertaking real-world researches in the short term and clinical phase II and phase III researches in the future to support the registration and marketing of overseas rare disease products in China, hosting and participating in domestic rare disease professional academic activities and patient organization activities, so as to help improve the awareness and the level of diagnosis and treatment for rare diseases.


    Establishment of Bo’ao Winhealth Rare Disease Medical Center in Hainan Province

     

    At the conference, Hao Jinghui, Co-CEO of Winhealth Pharma Group (HK), and Francois Liot, China region general manager of Ethypharm Pharmaceutical Co. Ltd., signed an agreement on Orphacol® (cholic acid capsules), a rare disease product for the treatment of congenital bile acid synthesis defect.

     

    Finally, the Center's first symposium of rare disease experts, which was sponsored by Shanghai Foundation for Rare Disease, was successfully held. The experts and other participants actively discussed the whole-process management of patients with rare diseases and demands of relevant drugs, which enhanced the exchange and cooperation between both sides.

     

    It is believed that with the support and promotion of governments and leaders of all authorities, and with the strong support of national rare disease-related societies, expert groups and patient organizations as well as domestic and foreign manufacturers, Bo’ao Winhealth Rare Disease Medical Center will continue to practice the purpose of China Alliance for Rare Disease, constantly enrich and improve its service functions, and strive to become a clinical center with the most comprehensive and advanced rare disease products and with the top-end diagnosis and treatment services in China, Southeast Asia and other surrounding areas, actively promote the synchronization with the advanced international level in technology, drugs and equipment, and make contributions to the development of rare diseases in China and to the health of people!


    *The drugs mentioned in this information have not been registered in China and are only available for prescription and/or use in Hainan Boao Lecheng International Medical Tourism Pilot Zone with special approval according to relevant regulations.



    3rd Floor, Winhealth Industrial Park, No. 272 Huancheng East Road, Xiacheng District, Hangzhou, Zhejiang, China
    BD@winhealth.Hk (overseas)
    0571-8718 6358    4008393773 ( Product Hotline )
    Copyright ©2019 - 2024 Zhejiang Medical Technology Development Co., Ltd.